Polaris Group (TPE:6550) Change In Receivables : NT$-9.13 Mil (TTM As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Polaris Group Change In Receivables?

Polaris Group's change in receivables for the quarter that ended in Mar. 2025 was NT$-20.69 Mil. It means Polaris Group's Accounts Receivable increased by NT$20.69 Mil from Dec. 2024 to Mar. 2025 .

Polaris Group's change in receivables for the fiscal year that ended in Dec. 2024 was NT$1.00 Mil. It means Polaris Group's Accounts Receivable declined by NT$1.00 Mil from Dec. 2023 to Dec. 2024 .

Polaris Group's Accounts Receivable for the quarter that ended in Mar. 2025 was NT$5.03 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Polaris Group's Days Sales Outstanding for the three months ended in Mar. 2025 was 54.41.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Polaris Group's liquidation value for the three months ended in Mar. 2025 was NT$77.44 Mil.

Polaris Group Change In Receivables Historical Data

The historical data trend for Polaris Group's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Polaris Group Change In Receivables Chart

Polaris Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-7.84

2.80

4.83

3.77

1.00

Polaris Group Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															-10.56	-31.59	38.68	4.47	-20.69

Polaris Group Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-9.13 Mil.

Polaris Group (TPE:6550) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Polaris Group's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	5.025	/	8.428	*	91
=	54.41

2. In Ben Graham's calculation of liquidation value, Polaris Group's accounts receivable are only considered to be worth 75% of book value:

Polaris Group's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2829.897	-	2806.323	+	0.75 * 5.025	+	0.5 * 100.201
=	77.44

Polaris Group Change In Receivables Related Terms

Thank you for viewing the detailed overview of Polaris Group's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Polaris Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Polaris Group (TPE:6550) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

NO.298, Ruiguang Road, 7th floor, Neihu District, Taipei, TWN

Website

https://www.polarispharma.com

Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. The company's lead therapeutic Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Polaris Group is also involved in every stage of the drug development process.

Polaris Group Headlines

No Headlines